Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 3UNKNOWN 1OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 36Stomach Neoplasms 19Esophageal Neoplasms 17Carcinoma, Non-Small-Cell Lung 13Colorectal Neoplasms 12Rectal Neoplasms 11Triple Negative Breast Neoplasms 9Brain Neoplasms 8Small Cell Lung Carcinoma 7Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Nasopharyngeal Carcinoma 4Melanoma 4Lymphoma, Extranodal NK-T-Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Recurrence 3Meningeal Carcinomatosis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Colonic Neoplasms 3Vomiting 2Urinary Bladder Neoplasms 2Skin Diseases 2Sarcoma 2

Interventions

S 1 (combination) 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Interventional × Breast Cancer Recurrent × Clear all
NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
300 enrolled
Breast

Breast Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡